arrow
T

Tareq A. Juratli

university hospital carl gustav carus
H指数:29
被引数:2,988

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems

脑膜瘤复发风险估计值在不同观察队列中的差异:日历时间、WHO分类、地理环境和医疗系统的影响

2026-08-280
OAAI
Fractionated radiotherapy adjuvant to surgery of WHO-2 meningioma with and without gross total resection: a multicenter, retrospective cohort study of 1,452 patients

WHO-2型脑膜瘤手术辅助分次放射治疗的疗效比较:一项包含1,452例患者的多中心回顾性队列研究(分为全切除与非全切除两组)

2026-02-090
OAAI
Molecular landscape and clinical correlates of olfactory groove meningiomas: a multi-institutional study

嗅沟脑膜瘤的分子图谱及临床相关性:一项多中心研究

2025-12-010
PRE
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomas

全球DNA高甲基化丢失是IDH突变型和1p/19q共缺失型少突胶质细胞瘤的预后指标。

2025-11-260
OAAI
Prognostic value of the Therapy-Disability-Neurology (TDN) Scale for surgical adverse events in glioblastoma: a multi-center analysis

胶质母细胞瘤手术不良事件中治疗-残疾-神经学(TDN)量表预测价值的多中心分析

2025-11-010
OAAI
The concept, intention, and evaluation of the term treatment-refractory meningioma

该术语的概念、意图和对治疗抵抗性脑膜瘤的评估

2025-08-040
OA
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted, and TERTp-wildtype: A grade 1 oligodendroglioma of young patients?

少突胶质细胞瘤,IDH突变型,1p/19q共缺失和TERTp野生型的独特分子特征与预后:是年轻患者的1级少突胶质细胞瘤?

2025-08-010
PRE
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

WHO 4级IDH突变型胶质瘤的多中心临床分析: 预后和临床试验设计的意义

2024-10-210
OAAI